Moe Thuzar

Dr. Moe Thuzar

1. Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2014 in Physiological Reports
Verified
Journal Article
Open access
PDF file
CJChristina Jang
Christina Jang
SJSandya Jalapu
Sandya Jalapu
Moe ThuzarMoe Thuzar
Moe Thuzar
PLPhillip W Law
Phillip W Law
SJSusanne Jeavons
Susanne Jeavons
KHKen K.Y. Ho
Ken K.Y. Ho
PET‐CT using 18F‐FDG is employed for detecting brown adipose tissue (BAT) in humans. Alternative methods are needed because of the radiation and cost of PET‐CT imaging. The aim was to evaluate the accuracy of infrared thermography (IRT) in detecting human BAT benchmarked to PET‐CT imaging. Seventeen individuals underwent a total of 29 PET‐CT scans, 12 of whom were studied twice, after 2 h of cold stimulation at 19°C, in parallel with measurement of skin temperatures overlying the supraclavicular (SCV) fossa and the lateral upper chest (control), before and after cold stimulation. Of the 29 scans, 20 were BAT positive after cold stimulation. The mean left SCV temperature tended to be higher in the BAT‐positive group before and during cooling. It was significantly higher ( P = 0.04) than the temperature of the control area, which fell significantly during cooling in the BAT‐positive (−1.2 ± 0.3°C, P = 0.002) but not in the negative (−0.2 ± 0.4°C) group. The temperature difference (Δtemp) between left SCV and chest increased during cooling in the BAT‐positive (1.2 ± 0.2 to 2.0 ± 0.3°C, P < 0.002) but not in the negative group (0.6 ± 0.1 to 0.7 ± 0.1°C). A Δtemp of 0.9°C conferred a positive predictive value of 85% for SCV BAT, superior to that of SCV temperature. The findings were similar on the right. In conclusion, the Δtemp is significantly and consistently greater in BAT‐positive subjects. The Δtemp quantified by IRT after 2‐h cooling shows promise as a noninvasive convenient technique for studying SCV BAT function.

2 November 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
Moe ThuzarMoe Thuzar
Moe Thuzar
KYKaren Young
Karen Young
AAAshraf H Ahmed
Ashraf H Ahmed
GWGreg Ward
Greg Ward
MWMartin Wolley
Martin Wolley
MSMichael Stowasser
Michael Stowasser
Background In primary aldosteronism (PA), excessive, autonomous secretion of aldosterone is not suppressed by salt loading or fludrocortisone. For seated saline suppression testing (SSST), the recommended diagnostic cut-off 4-hour plasma aldosterone concentration (PAC) measured by HPLC-MS/MS is 162pmol/L. Most diagnostic laboratories, however, use immunoassays to measure PAC. The cut-off for SSST using immunoassay is not known. We hypothesized that the cut-off is different between the assays. Methods We analysed 80 of the 87 SSST tests that were performed during the recent study defining the HPLC-MS/MS cut-off. PA was confirmed in 65 by positive fludrocortisone suppression testing (FST) and/or lateralisation on adrenal venous sampling and excluded in 15 by negative FST. PAC was measured by a chemiluminescence immunoassay (PACIA) in the SSST samples using the DiaSorin Liaison XL analyser, and receiver operating characteristics (ROC) analysis was performed to identify the PACIA cut-off. Results ROC revealed good performance (AUC=0.893; P<0.001) of 4-hour post saline PACIA for diagnosis of PA and an optimal diagnostic cut-off of 171pmol/L, with sensitivity and specificity of 95.4% and 80.0% respectively. A higher cut-off of 217pmol/L improved specificity (86.7%) with a lower sensitivity (86.2%). PACIA measurements strongly correlated with PAC measured by HPLC-MS (r=0.94, P<0.001). Conclusions A higher diagnostic cut-off for SSST should be employed when PAC is measured by immunoassay rather than HPLC-MS/MS. The results suggest that (i) PA can be excluded if 4-hour PACIA is 217pmol/L by chemiluminescence immunoassay. A grey zone exists between cut-offs of 171 and 217pmol/L, likely reflecting a lower specificity of immunoassay.

17 September 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
Moe ThuzarMoe Thuzar
Moe Thuzar
WLWeikiat Phillip Law
Weikiat Phillip Law
GDGoce Dimeski
Goce Dimeski
MSMichael Stowasser
Michael Stowasser
KHKen K. Y. Ho
Ken K. Y. Ho

6 December 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
Moe ThuzarMoe Thuzar
Moe Thuzar
WLWeikiat Phillip Law
Weikiat Phillip Law
JRJeyakantha Ratnasingam
Jeyakantha Ratnasingam
CJChristina Jang
Christina Jang
GDGoce Dimeski
Goce Dimeski
KHKen K. Y. Ho
Ken K. Y. Ho

20 December 2022 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
SKShelley Keating
Shelley Keating
ICIlaria Croci
Ilaria Croci
MWMatthew P. Wallen
Matthew P. Wallen
ECEmily R. Cox
Emily R. Cox
Moe ThuzarMoe Thuzar
Moe Thuzar
IHIngrid Hickman
Ingrid Hickman
Background High-Intensity Interval Training (HIIT) involves bursts of high-intensity exercise interspersed with lower-intensity exercise recovery. HIIT may benefit cardiometabolic health in people with nonalcoholic steatohepatitis (NASH). Aims We aimed to examine the safety, feasibility, and efficacy of 12-weeks of supervised HIIT compared with a sham-exercise control (CON) for improving aerobic fitness and peripheral insulin sensitivity in biopsy-proven NASH. Methods Participants based in the community [(n = 14, 56 ± 10 years, BMI 39.2 ± 6.7 kg/m2, 64% male), NAFLD Activity Score 5 (range 3–7)] were randomized to 12-weeks of supervised HIIT (n = 8, 4 × 4 min at 85–95% maximal heart rate, interspersed with 3 min active recovery; 3 days/week) or CON (n = 6, stretching; 3 days/week). Safety (adverse events) and feasibility determined as ≥ 70% program completion and ≥ 70% global adherence (including session attendance, interval intensity adherence, and duration adherence) were assessed. Changes in cardiorespiratory fitness (V̇O2peak), exercise capacity (time-on-test) and peripheral insulin sensitivity (euglycemic hyperinsulinemic clamp) were assessed. Data were analysed using ANCOVA with baseline value as the covariate. Results There were no HIIT-related adverse events and HIIT was globally feasible [program completion 75%, global adherence 100% (including adherence to session 95.4 ± 7.3%, interval intensity 95.3 ± 6.0% and duration 96.8 ± 2.4%)]. A large between-group effect was observed for exercise capacity [mean difference 134.2 s (95% CI 19.8, 248.6 s), ƞ2 0.44, p = 0.03], improving in HIIT (106.2 ± 97.5 s) but not CON (− 33.4 ± 43.3 s), and for peripheral insulin sensitivity [mean difference 3.4 mg/KgLegFFM/min (95% CI 0.9,6.8 mg/KgLegFFM/min), ƞ2 0.32, p = 0.046], improving in HIIT (1.0 ± 0.8 mg/KgLegFFM/min) but not CON (− 3.1 ± 1.2 mg/KgLegFFM/min). Conclusions HIIT is safe, feasible and efficacious for improving exercise capacity and peripheral insulin sensitivity in people with NASH. Clinical Trial Registration Number Australian New Zealand Clinical Trial Registry (anzctr.org.au) identifier ACTRN12616000305426 (09/03/2016). Graphical Abstract

1 April 2014 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
Moe ThuzarMoe Thuzar
Moe Thuzar
UMUsman Malabu
Usman Malabu
BTBen Tisdell
Ben Tisdell
KSKunwarjit S. Sangla
Kunwarjit S. Sangla